Frosch, Zachary A. K.
Jacobs, Lisa M.
O’Brien, Caroline S.
Brecher, Alison C.
McKeown, Colleen J.
Lynch, Shannon M.
Geynisman, Daniel M.
Hall, Michael J.
Edelman, Martin J.
Bleicher, Richard J.
Fang, Carolyn Y.
Article History
Received: 26 July 2023
Accepted: 21 November 2023
First Online: 7 December 2023
Declarations
:
: This study was approved by the Fox Chase Cancer Center Institutional Review Board (#21-8013).
: All participants provided informed consent to participate in this study.
: Dr. Frosch reports grants from the Conquer Cancer Foundation of ASCO in support of this study and the following unrelated to the conduct of this study: Advisory Board fees from Seagen, research funds to institution from Roche, AstraZenica, and Abbvie. Dr Lynch reported personal fees from Beautycounter for serving as a consultant outside the submitted work. Dr Hall reports serving on advisory boards for Natera and Eisai outside the submitted work. Dr Edelman reports serving as a member of data safety monitoring boards for AstraZeneca, Takeda, GlaxoSmithKline, Seagen; serving on advisory boards for GE Health Care, Omega Therapeutics, BioAltaBioAtla, Regeneron/Sanofi, Novocure, InterVenn, Flame; and holding stock options for Creatv MicrotTech, all outside of the submitted work. Dr. Bleicher reports consulting fees for Elucent Medical unrelated to this study.
: Any opinions, findings, and conclusions expressed in this material are those of the author(s) and do not necessarily reflect those of the American Society of Clinical Oncology or Conquer Cancer.